Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4531-4536

  Tomov, Bojidar ^a   Popov, Dimitar ^a   Tomova, Radosveta ^a   Vladov, Nicola ^b   Otter, Willem Den ^c   Krastev, Zachary ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b MILITARY MEDICAL ACADEMY   (Bulgaria)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCG; HCC; Hepatocellular carcinoma; IL 2; Immunotherapy; Interleukin 2; Melatonin

Indexed keywords

ALPHA FETOPROTEIN; BCG VACCINE; INTERLEUKIN 2; MELATONIN; RECOMBINANT INTERLEUKIN 2;

ABSENCE OF SIDE EFFECTS; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SIZE; CASE REPORT; CHRONIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER INJURY; LIVER RESECTION; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SKIN SCAR; TREATMENT DURATION; TREATMENT RESPONSE;

BCG; HCC; HEPATOCELLULAR CARCINOMA; IL-2; IMMUNOTHERAPY; INTERLEUKIN-2; MELATONIN;

AGED; ALPHA-FETOPROTEINS; BCG VACCINE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-2; LIVER NEOPLASMS; MELATONIN; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84891353813     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. Kew MC: Tumour markers of hepatocellular carcinoma. J Gastroenterol Hepatol 4 : 373-384, 1989.
3. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S and Montalto G: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 23 : 1747-1753, 2003.
4. Sacco R, Bargellini I, Ginanni B, Bertini M, Faggioni L, Federici G, Romano A, Bertoni M, Metrangolo S, Altomare E, Parisi G, Tumino E, Scaramuzzino A, Bresci G and Bartolozzi C: Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: What can we learn from routine clinical practice? Expert Rev Anticancer Ther 12: 869-875, 2012.
5. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE and Morris JC: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113: 1515-1525, 2004.
6. Baluna R and Vitetta E: Vascular leak syndrome: A side-effect of immunotherapy. Immunopharmacology 37: 117-132, 1997.
7. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin 2 therapy. J Clin Oncol 13: 688-696, 1995.
8. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT and Rosenberg SA: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117-3124, 1986.
9. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C, Roy SE, Shearer RJ, Marsden RA, Bevan D and Gordon-Smith EC: The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2. Br J Cancer 63 : 275-278, 1991.
10. Meloni G, Trisolini SM, Capria S, Torelli GF, Baldacci E, Torromeo C, Valesini G and Mandelli F: How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia 16 : 2016-2018, 2002.
11. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, and Martignetti A: Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 25: 224-226, 2002.
12. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A and Maestroni GJ: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 30A : 167-170, 1994.
13. Den Otter W, Van Moorselaar RJE, Jacobs JJL, Ter Haar R, Koten JW, Dobrowolski Z, Lipczynski W, Pasukoniene V, Characiejus D, Jankevicius F, Eidukevicius R and De Reijke TM: Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder carcinoma. Comparison of the therapeutic affect in two pilot studies. Anticancer Res 33: 2099-2106, 2013.
14. Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K and Asahara T: Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43: 362-372, 2006.
15. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA and Jaffe ES: The immunopathology of sequential tumor biopsies in patients treated with interleukin 2: Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129: 208-216, 1987.
16. Domskov F and Von der Maase HV: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997-2005, 2006.
17. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PGPM and Koten JW: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57: 931-950, 2008.
18. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I and Cardinali DP: Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7: 189-203, 2008.
19. Jung B and Ahmad N: Melatonin in cancer management: progress and promise. Cancer Res 66 : 9789-9793, 2006.
20. Wu X, Patterson S and Hawk E: Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 25:445-459,2011.
21. Shi M, Zhang CQ, Zhang YQ, Liang XM and Li JQ: Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 28: 376-381, 2004.
22. Tanaka K, Zhang CQ, Zhang YQ, Liang XM and Li JQ: Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery 143: 607-615, 2008.
23. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846, 2007.
24. Christophi C, Harun N and Fifis T: Liver regeneration and tumor stimulation: A review of cytokine and angiogenic factors. J Gastrointest Surg 12 : 966-980, 2008.
25. Chen JA, Shi M, Li JQ and Qian CN: Angiogenesis: Multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int 4: 537-547, 2010.